BOULDER, Colo., Feb. 10 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today announced that it has filed a preliminary proxy related to the special meeting of shareholders required to approve the recently announced financing as well as related matters tied to its equity incentive plans. The text of this filing can be viewed at the SEC EDGAR website at http://www.sec.gov/cgi-bin/browse- edgar?type=pre+14&dateb=&owner=exclude&count=40&action=getcompany&CIK=00008915 04.
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a company focused on the development of proprietary therapies for the treatment of cancer.
For more information about Tapestry and its technologies, visit Tapestry’s web site at www.tapestrypharma.com.
For further information, please contact Gordon Link, Senior Vice President, Chief Financial Officer, at 303 516 8500.
Tapestry Pharmaceuticals, Inc.
CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer ofTapestry Pharmaceuticals, Inc., +1-303-516-8500, glink@tapestrypharma.com;or Investors, Michael Wachs of CEOcast, Inc., +1-212-732-4300, for TapestryPharmaceuticals, Inc.; or Media, Peter Steinerman, +1-516-374-3031, forTapestry Pharmaceuticals, Inc.
Web site: http://www.tapestrypharma.com/
